Pathogen reduction combined with rapid diagnostic tests to reduce the risk of transfusion-transmitted infections in Uganda

Transfusion

Volumn 58, Issue 4, 2018, Pages 854-861

  Butler, Elissa K ^a,b   McCullough, Jeffrey ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN;

ANTIBODY DETECTION; ARTICLE; BLOOD SAFETY; BLOOD TRANSFUSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; POPULATION RESEARCH; PROBABILITY; RISK REDUCTION; UGANDA; ULTRAVIOLET PHOTOTHERAPY; VASCULARIZATION; BLOOD; BLOOD TRANSFUSION REACTION; BLOODBORNE BACTERIUM; DEVELOPING COUNTRY; HEALTH CARE QUALITY; PHOTOCHEMISTRY; PROCEDURES; PROOF OF CONCEPT; RADIATION RESPONSE; SENSITIVITY AND SPECIFICITY; THEORETICAL MODEL; TRANSMISSION; ULTRAVIOLET RADIATION; VIREMIA; VIRUS INACTIVATION;

BLOOD SAFETY; BLOOD-BORNE PATHOGENS; DEVELOPING COUNTRIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALARIA; MODELS, THEORETICAL; PHOTOCHEMICAL PROCESSES; PROBABILITY; PROOF OF CONCEPT STUDY; QUALITY ASSURANCE, HEALTH CARE; RIBOFLAVIN; SENSITIVITY AND SPECIFICITY; TRANSFUSION REACTION; UGANDA; ULTRAVIOLET RAYS; VIREMIA; VIRUS INACTIVATION;

EID: 85041614014     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14497     Document Type: Article

References (40)

1. Blood safety and availability: fact sheet [Internet]. Geneva: World Health Organization. 2017 [cited 2018 Jan 17]. Available from: http://www.who.int/mediacentre/factsheets/fs279/en/.
2. Global status report on blood safety and availability 2016 [Internet]. >Geneva: World Health Organization. 2017 [cited 2017 Oct 12]. Available from: http://apps.who.int/iris/bitstream/10665/254987/1/9789241565431-eng.pdf.
3. Allain JP, Sarkodie F, Asenso-Mensah K, et al. Relative safety of first-time volunteer and replacement donors in West Africa. Transfusion 2010;50:340-3.
4. Dybul M. Partnerships for blood safety in Africa: the US President's emergency plan for AIDS relief. Transfusion 2008;48:1044-6.
5. Vermeulen M, Dickens C, Lelie N, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 2012;52:880-92.
6. Vermeulen M, Lelie N, Sykes W, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-25.
7. Jayaraman S, Chalabi Z, Perel P, et al. The risk of transfusion-transmitted infections in sub-Saharan Africa. Transfusion 2010;50:433-42.
8. McCullough J. Pathogen inactivation: a new paradigm for blood safety. Transfusion 2007;47:2180-4.
9. Webert KE, Cserti C, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation—making decisions about new technologies. Transfus Med Rev 2008;22:1-34.
10. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007;47:2338-47.
11. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
12. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
13. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-73.
14. McCullough J, Goldfinger D, Gorlin J, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion 2015;55:2312-20.
15. Allain JP, Owusu-Ofori A, Assennato SM, et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016;387:1753-61.
16. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002;42:537-48.
17. Butler EK, Hume H, Birungi I, et al. Blood utilization at a national referral hospital in sub-Saharan Africa. Transfusion 2015;55:1058-66.
18. Keil SD, Bengrine A, Bowen R, et al. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015;55:1736-44.
19. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877-85.
20. Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al. Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage. Shock 2015;44Suppl 1:33-8.
21. Keil SD, Kiser P, Sullivan JJ, et al. Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013;53:2278-86.
22. The HIV and AIDS Uganda Country Progress Report 2014 [Internet]. Kampala: UNAIDS; 2015 [cited 2016 Aug 22]. Available from: http://www.unaids.org/sites/default/files/country/documents/UGA_narrative_report_2015.pdf.
23. Tapko JB, Toure B, Sambo LG. Status of blood safety in the WHO African region: report of the 2010 survey. Brazzaville: World Health Organization Regional Office for Africa; 2014 [cited 2016 Aug 20]. Available from: http://www.afro.who.int/sites/default/files/2017-06/status-of-blood-safety-in-the-who-african-region.pdf.
24. Owusu-Ofori AK, Parry C, Bates I. Transfusion-transmitted malaria in countries where malaria is endemic: a review of the literature from sub-Saharan Africa. Clin Infect Dis 2010;51:1192-8.
25. Chavez M, Wesolowski K, Patel P, et al. Evaluation of the performance of the Abbott Architect HIV Ag/Ab combo assay. J Clin Virol 2011;52Suppl 1:S51-5.
26. Architect system: HBsAg [Internet]. Abbott Park (IL): Abbott Diagnostics Division; 2008 [cited 2018 Jan 17]. Available from: http://www.ilexmedical.com/files/PDF/HBsAg_ARC.pdf.
27. Park Y, Lee JH, Kim BS, et al. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010;48:2253-6.
28. Alere Determine™ HIV-1/2 Ag/Ab Combo [Internet]. Orlando (FL): Alere North America Inc. 2012 [cited 2015 Mar 21]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM364698.pdf.
29. Randrianirina F, Carod JF, Ratsima E. Evaluation of the performance of four rapid tests for detection of hepatitis B surface antigen in Antananarivo, Madagascar. J Virol Methods 2008 Aug;151:294-7.
30. Lee SR, Kardos KW, Schiff E, et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods 2011;172:27-31.
31. Malaria rapid diagnostic test performance. Summary results of WHO product testing of malaria RDTs: Round 1-5 (2008-2013) [Internet]. Geneva: World Health Organization; 2014 [cited 2015 Nov 11]. Available from: http://www.who.int/malaria/publications/atoz/9789241507554-summary_eng.pdf.
32. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
33. Fraser C, Hollingsworth TD, Chapman R, et al. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 2007;104:17441-6.
34. Allain JP, Candotti D, Soldan K, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003;101:2419-25.
35. Neumann AU, Lam NP, Dahari LH, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
36. Kinde-Gazard J, Oke I, Gnahoui A, et al. [The risk of malaria transmission by blood transfusion at Cotonou, Benin]. Santé 2000;10:389-92.
37. Cohen MS, Gay CL, Busch MP, et al. The detection of acute HIV infection. J Infect Dis 2010;202 Suppl 2:S270-7.
38. Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005;45:994-1002.
39. Icardi G, Ansaldi F, Bruzzone BM, et al. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol 2001;39:3110-4.
40. Laperche S; Francophone African Group for Research in Blood Transfusion. Multinational assessment of blood-borne virus testing and transfusion safety on the African continent. Transfusion 2013;53:816-26.